About RSV

RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States.

Each year, 57,000 to 125,000 children in this age group are hospitalized due to RSV infection. Children with compromised (weakened) immune systems due to a medical condition or medical treatment, adults with compromised immune systems and those 65 and older are also at increased risk of severe disease.

Respiratory Syncytial Virus (RSV)


Respiratory Syncytial Virus is a virus that infects the lungs and represents a serious unmet medical need in infants and children, as well as immune-compromised individuals and the elderly. RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one. In one large U.S.-based study, RSV infection in children was associated with 20% of hospitalizations, 18% of emergency department visits, and 15% of pediatric office visits for acute respiratory infections in the November-April time frame. Though a prophylactic monoclonal antibody-based treatment is available for those considered at high risk for RSV infection, this study found that most young children affected by RSV infection were previously healthy, and thus would not normally be considered for prophylaxis. There is currently no effective treatment available for treating RSV infection.

Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV. Pre-clinical data demonstrated a rapid reduction in viral load, below the limits of detection (LOD) in animals treated with EDP-938. EDP-938 is being studied in a Phase 2 challenge study with results expected mid-2019.

For an overview of our research, including our licensed products, please see Our Pipeline.